^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunostimulant

    Related drugs:
    2d
    Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years) (clinicaltrials.gov)
    P1, N=175, Completed, Sanofi Pasteur, a Sanofi Company
    New P1 trial
    2d
    Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above (clinicaltrials.gov)
    P2, N=924, Active, not recruiting, MAXVAX Biotechnology Limited Liability Company | Trial primary completion date: Feb 2024 --> Dec 2024
    Trial primary completion date
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2)
    2d
    KEYNOTE-E58: Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors (clinicaltrials.gov)
    P1/2, N=115, Active, not recruiting, Nouscom SRL | Recruiting --> Active, not recruiting | Trial completion date: Jul 2026 --> Nov 2026
    Enrollment closed • Trial completion date
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • NOUS-209
    2d
    Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers (clinicaltrials.gov)
    P2, N=1512, Active, not recruiting, MAXVAX Biotechnology Limited Liability Company | Trial completion date: Apr 2024 --> Dec 2024
    Trial completion date
    2d
    REVIVE (Response to the Ebola Virus Vaccine) (clinicaltrials.gov)
    P4, N=40, Not yet recruiting, Tulane University | Trial completion date: Mar 2025 --> Aug 2025 | Trial primary completion date: Mar 2025 --> Jul 2025
    Trial completion date • Trial primary completion date
    2d
    A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults (clinicaltrials.gov)
    P1, N=26, Terminated, National Cancer Institute (NCI) | Completed --> Terminated; Study closed due to low accrual.
    Trial termination
    |
    CD4 (CD4 Molecule)
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    2d
    An Exploratory Clinical Study to Evaluate the Safety, Tolerability, Immune Response and Preliminary Efficacy of LM103 Injection in Combination With PD-1 in Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=10, Recruiting, Suzhou BlueHorse Therapeutics Co., Ltd.
    New P1 trial • Combination therapy • Metastases
    |
    cyclophosphamide • LM103
    3d
    Characteristics of a CCL21-gene modified dendritic cell vaccine utilized for a clinical trial in non-small cell lung cancer. (PubMed, Mol Cancer Ther)
    We have embarked on a phase I clinical trial of a vaccine consisting of monocyte-derived DCs (moDCs) modified to express the chemokine CCL21 (CCL21-DC) given in combination with pembrolizumab. A single freeze-thaw cycle for stored vaccines was associated with minor alterations to the DC phenotype, as was the use of healthy donors rather than patient autologous blood. Our results highlight important considerations for the production of DC vaccines and identify underexplored factors that may affect their efficacy and immunologic impact.
    Journal
    |
    CCL21 (C-C Motif Chemokine Ligand 21)
    |
    Keytruda (pembrolizumab) • Ad-CCL21-DC
    3d
    Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis (clinicaltrials.gov)
    P4, N=200, Recruiting, Mercy Medical Center | Trial completion date: Jul 2024 --> Dec 2028 | Trial primary completion date: Jul 2024 --> Dec 2028
    Trial completion date • Trial primary completion date
    3d
    S4V03: A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine (clinicaltrials.gov)
    P2, N=120, Recruiting, LimmaTech Biologics AG | Not yet recruiting --> Recruiting
    Enrollment open
    3d
    CASE6119: Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer (clinicaltrials.gov)
    P1, N=45, Recruiting, George T. Budd | Trial completion date: Mar 2025 --> Nov 2025 | Trial primary completion date: Nov 2024 --> May 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • PRL (Prolactin)
    |
    BRCA1 mutation • HER-2 negative • PALB2 mutation • ER negative • PGR negative
    |
    alpha-lactalbumin vaccine
    3d
    Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age (clinicaltrials.gov)
    P3, N=2450, Not yet recruiting, ModernaTX, Inc.
    New P3 trial
    3d
    LOKON002: Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer (clinicaltrials.gov)
    P1/2, N=47, Completed, Lokon Pharma AB | Active, not recruiting --> Completed
    Trial completion • Oncolytic virus
    |
    delolimogene mupadenorepvec (LOAd703)
    3d
    Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe. (clinicaltrials.gov)
    P=N/A, N=670, Not yet recruiting, Sanofi
    New trial
    4d
    Safety and Immunogenicity of V540B in Healthy Adults (V540B-002) (clinicaltrials.gov)
    P1, N=72, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    4d
    A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age (clinicaltrials.gov)
    P3, N=750, Not yet recruiting, GlaxoSmithKline
    New P3 trial
    4d
    A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults (clinicaltrials.gov)
    P2, N=325, Active, not recruiting, ModernaTX, Inc. | N=98 --> 325
    Enrollment change
    7d
    Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (clinicaltrials.gov)
    P1/2, N=750, Recruiting, Sanofi Pasteur, a Sanofi Company | Not yet recruiting --> Recruiting
    Enrollment open
    7d
    COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults (clinicaltrials.gov)
    P1, N=41, Completed, ImmunityBio, Inc. | Active, not recruiting --> Completed | Phase classification: P1b --> P1
    Trial completion • Phase classification
    7d
    Study of the Impact of Time of Vaccination on Response to Influenza Vaccine in Kidney Transplant Recipients -ChronoVAX (clinicaltrials.gov)
    P=N/A, N=38, Completed, Centre Hospitalier Universitaire de Nice | Recruiting --> Completed | N=100 --> 38 | Trial completion date: Oct 2024 --> Jun 2024 | Trial primary completion date: Oct 2024 --> Jun 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    7d
    Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers (clinicaltrials.gov)
    P3, N=4000, Active, not recruiting, Cellid Co., Ltd. | Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2024 --> Mar 2025
    Enrollment closed • Trial primary completion date
    8d
    Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer (clinicaltrials.gov)
    P2, N=29, Recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2027 --> Nov 2028 | Trial primary completion date: Nov 2024 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • PRGN-2009
    8d
    Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran) (clinicaltrials.gov)
    P=N/A, N=660, Active, not recruiting, Pfizer | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    8d
    A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004) (clinicaltrials.gov)
    P1, N=72, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1 trial
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    9d
    Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older (clinicaltrials.gov)
    P1/2, N=1470, Not yet recruiting, Sanofi Pasteur, a Sanofi Company
    New P1/2 trial
    9d
    HORIZON 1: A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19) (clinicaltrials.gov)
    P2, N=51, Completed, Janssen Vaccines & Prevention B.V. | N=98 --> 51
    Enrollment change
    9d
    A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age (clinicaltrials.gov)
    P1/2, N=1080, Completed, GlaxoSmithKline | Active, not recruiting --> Completed | Phase classification: P2 --> P1/2
    Trial completion • Phase classification
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    10d
    A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People (clinicaltrials.gov)
    P1/2, N=1350, Not yet recruiting, BioNTech SE
    New P1/2 trial
    10d
    FPCV: The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants (clinicaltrials.gov)
    P4, N=2100, Completed, London School of Hygiene and Tropical Medicine | Active, not recruiting --> Completed
    Trial completion
    10d
    ROSALIE: First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma (clinicaltrials.gov)
    P1/2, N=100, Completed, Enterome | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Mar 2024 | Trial primary completion date: Dec 2024 --> Jan 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • EO2401
    10d
    Spencer: A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma (clinicaltrials.gov)
    P1/2, N=70, Terminated, Enterome | Active, not recruiting --> Terminated; Strategic decision
    Trial termination • Combination therapy • Checkpoint block • Metastases
    |
    Opdivo (nivolumab) • EO2401
    10d
    Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients (clinicaltrials.gov)
    P1/2, N=60, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    BRAF mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation
    |
    NOUS-209
    12d
    Clinical study on the protective mechanism of immune response of recombinant herpes zoster vaccine (CHO cell) based on multi-omics (ChiCTR2400090653)
    P1, N=80, Not yet recruiting, Wuxi Center for Disease Control and Prevention; Beijing Luzhu Biotechnology Co.,Ltd.
    New P1 trial
    |
    CD8 (cluster of differentiation 8) • IL2 (Interleukin 2) • CD40LG (CD40 ligand)
    12d
    Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Longkoma Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris) Implanted in Populations of 6 Weeks and Older (ChiCTR2400089762)
    P1/2, N=580, Completed, Guangxi Zhuang Autonomous Region Centre for Disease Control and Prevention; Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
    New P1/2 trial
    14d
    PRGN-2009-201: PRGN-2009 in Combination with Pembrolizumab Versus Pembrolizumab in Patients with Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov)
    P2, N=46, Recruiting, Precigen, Inc | Initiation date: Aug 2024 --> Nov 2024
    Trial initiation date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • PRGN-2009
    14d
    A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults (clinicaltrials.gov)
    P1/2, N=402, Not yet recruiting, SK Bioscience Co., Ltd.
    New P1/2 trial
    14d
    Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients (clinicaltrials.gov)
    P2, N=90, Recruiting, University of California, Davis | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
    Trial completion date • Trial primary completion date
    14d
    A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases (clinicaltrials.gov)
    P3, N=39, Recruiting, Takeda | Not yet recruiting --> Recruiting
    Enrollment open
    15d
    A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination with an Investigational RNA-based Vaccine Against Malaria (clinicaltrials.gov)
    P1/2, N=177, Active, not recruiting, BioNTech SE | Recruiting --> Active, not recruiting
    Enrollment closed
    15d
    Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years (clinicaltrials.gov)
    P1, N=390, Recruiting, Sanofi Pasteur, a Sanofi Company | Not yet recruiting --> Recruiting
    Enrollment open
    15d
    Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-blocking Activity in Healthy Malaria-naive Adults (clinicaltrials.gov)
    P1, N=59, Active, not recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting --> Active, not recruiting | N=200 --> 59 | Trial completion date: May 2025 --> Nov 2025 | Trial primary completion date: May 2025 --> Nov 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    16d
    LYL845-101: A Study to Investigate LYL845 in Adults With Solid Tumors (clinicaltrials.gov)
    P1, N=108, Active, not recruiting, Lyell Immunopharma, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • BRAF mutation
    |
    LYL845